More effective than enrofloxacin-based monodrugs with comparable cost of treatment
Long-time use of the drug due to low development of resistance of microorganisms compared to enrofloxacin-based monodrugs
Highly effective against colibacillosis
Synergistic effect of the drug components.
A complex drug that is highly effective against colibacteriosis, to which resistance is slowly developing due to the synergistic effect of enrofloxacin and colistin.
Enronit is a transparent or opalescent light yellow liquid.
Packing: 50 and 100 mL glass bottles filled with a sterile solution.
50 mg enrofloxacin
500 000 IU colistin
The synergistic combination of enrofloxacin and colistin sulfate provides a broad-spectrum antimicrobial activity against Gram-positive and Gram-negative microbes.
Mode of action: enrofloxacin inhibits the activity of gyrase (an enzyme that affects the replication of DNA spiral in the nucleus of the bacterial cell), thus disrupting the protein synthesis and suppressing the growth and development of Gram-positive and Gramnegative bacteria including Escherichia coli, Haemophilus spp., Pasteurella spp., Salmonella spp., Staphylococcus spp., Streptococcus spp., Clostridium perfringens, Bordetella spp., Campylobacter spp., Corynebacterium pyogenes, Pseudomonas aeruginosa, and Mycoplasma spp. Colistin sulfate impairs the permeability of the bacterial cell walls by connecting to lypoproteins, that leads to a change in the intracellular metabolism and causes death of Gram-negative bacteria including Escherichia coli, Pseudomonas aeruginosa, Klebsiella spp, Salmonella spp., and Proteus spp.
Enronit is quickly resorbed from the injection site and distributed among the organs and tissues of an animal. Concentration of enrofloxacin in blood serum reaches its peak value after 1 to 2 hours, while concentration of colistin sulfate in blood serum reaches its peak value after 1 hour. Enrofloxacin and colistin sulfate are eliminated unchanged mostly with feces and partially with urine.
Enronit is prescribed to treat following diseases: for calves and lambs - colibacillosis, salmonellosis, pasteurellosis, respiratory, and other diseases caused by enrofloxacin- and colistin sulfate-sensitive microbes; for piglets - colibacillosis, salmonellosis, pasteurellosis, respiratory, and other diseases caused by enrofloxacin- and colistin sulfate-sensitive microbes; for adult pigs - atrophic rhinitis, enzootic pneumonia, and MMAsyndrome.
Enronit is administered subcutaneously to lambs and calves at a dose of 0.5 mL per 10 kg of animal body weight once per day for 3 to 5 days.
As a pain reaction may occur, avoid administering more than 5 mL to calves and more than 2.5 mL of the drug to lambs in one injection site.
Enronit is administered intramuscularly to pigs at a dose of 0.5 mL per 10 kg of animal body weight once per day for 3 to 5 days; to sows with MMAsyndrome - for 1 to 2 days.
As a pain reaction may occur, avoid administering more than 5 mL to pigs and more than 2.5 mLof the drug to piglets in one injection site.
Avoid using Enronit in milking cows, newborn calves, lambs, animals suffering from kidney and liver diseases, lesions of the nervous system, leading to seizures, as well as concurrently with chloramphenicol, macrolide antibiotics group and tetracycline, theophylline, and nonsteroidal anti-inflammatory agents.
Treated animals can be slaughtered for human consumption not earlier than 21 days after the last injection of Enronit was made. In the case of forced slaughter of animals before the established deadlines, the meat can be used for feeding fur-bearing animals.
2 years from the date of manufacture; after first opening - 28 days
If WhatsApp is installed on your computer, follow thelink and contact us.
If this program is not available, then please write to us directly from your mobile phone in Viber or WhatsApp at the number +7 965 880-47-56.
If Viber is installed on your computer, then follow the link and contact us.
If this program is not available, then please write to us directly from your mobile phone in Viber or WhatsApp at the number
+7 965 880-47-56.